Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P250033/S004

NEXUS Aortic Arch Stent Graft System

Endospan , Ltd. · Decision date Sep 21, 2026

MEDTECHLEDGER EXPLANATIONP250033/S004

What did the FDA approve?

The FDA record P250033/S004, decided 21 September 2026, is a Normal 180 Day Track supplement to PMA P250033 for the NEXUS Aortic Arch Stent Graft System, sponsored by Endospan, Ltd. The supplement reason is listed as a labeling change covering indications, instructions, shelf life, or tradename, and the stated decision is approval for a three-year shelf life.

The identifier shows this supplement shares the base PMA number of the original approval, so it modifies that file rather than establishing a new approval of the whole system. The record does not specify what labeling text changed, whether the shelf-life approval reflects real-time or accelerated data, or any clinical evidence, and it is not independent proof of safety or effectiveness; the device's original scope is described only as an endovascular system for treatment of ascending aorta and aortic arch lesions.

FDA approval order statement

approval for a 3 year shelf-life for the NEXUS Aortic Arch Stent Graft System
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track
Clinical specialty
Cardiovascular
Decision date
Sep 21, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P250033/S004
Regulatory pathway
PMA supplement
Product code
SDZ
Decision code
APPR
Decision date
Sep 21, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Endovascular System for Treatment of Ascending Aorta and Aortic Arch Lesions.

Product code
SDZ
FDA device class
3

For the original device and its historical approval scope, see PMA P250033. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P250033 · Original PMA

    NEXUS Aortic Arch Stent Graft System

  2. P250033/S001 · Related supplement

    NEXUS Aortic Arch Stent Graft System

  3. P250033/S004 received

    Application receipt date recorded by FDA.

  4. P250033/S002 · Related supplement

    NEXUS Aortic Arch Stent Graft System

  5. P250033/S004 · FDA decision

    Normal 180 Day Track

Timeline entries are records held by MedtechLedger for P250033. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P250033

Product / regulatory recordCompanyPathwayDecision dateSource
Endospan , Ltd.PMA approvalApr 2, 2026FDA
Endospan , Ltd.PMA supplementMay 20, 2026FDA
Endospan , Ltd.PMA supplementJul 24, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Endospan , Ltd.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
105 Alta Meadows Rd., Alta, WY, 83414

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records